Autoimmune Diseases; Cystic Fibrosis; Hepatitis; Liver; Liver Diseases
Public Health Interests
I am evaluating the role of an inflammatory protein called MIF in autoimmune hepatitis and its ability to be a predictor of disease severity, response to therapy, and a predictor of disease relapse.
I am evaluating mechanisms of disease and therapies for the treatment of Primary Sclerosing Cholangitis.
Extensive Research Description
I am investigating the role of macrophage migration inhibitory factor (MIF) in autoimmune hepatitis. Active studies involve serial measurement of serum MIF and its soluble receptor (CD74) in the blood of patients with autoimmune hepatitis, to evaluate if these proteins can serve as biomarkers of disease activity.
I am evaluating cellular mechanisms of the release of the CD74 protein and its neutralizing activity on the cytokine MIF.
I am investigating the role of MIF in the pathophysiology of autoimmune hepatitis in animal models of disease.
I am evaluating potential new therapies for Primary Sclerosing Cholangitis (PSC) including all-trans retinoic acid.
A study of the role of macrophage migration inhibitory factor (MIF) in autoimmune hepatitis, through clinical and translational investigations.
The role of macrophage migration inhibitory factor (MIF) in autoimmune liver disease.
Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, Mizue Y, Nikolic-Paterson DJ, Bernhagen J, Kaplan KM, Zhao H, Boyer JL, Bucala R. Hepatology. 2014;59:580-91.
A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients.
Assis DN, Takahashi H, Leng L, Zeniya M, Boyer JL, Bucala R. Dig Dis Sci. 2016 Dec;61(12):3506-3512.
- Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. Assis DN, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, Deng Y, Setchell KD, Ciarleglio M, Lindor KD, Boyer JL.
Gastrointestinal Disorders in Cystic Fibrosis.
Assis DN, Freedman SD. Clin Chest Med. 2016 Mar;37(1):109-18.
Editorial: environmental risk factors for PSC with and without IBD--the story unfolds.
Assis DN, Levy C. Aliment Pharmacol Ther. 2015 Jun;41(11):1214-6
Fibrates and cholestasis.
Ghonem NS, Assis DN, Boyer JL. Hepatology. 2015 Aug;62(2):635-43.